Mode
Text Size
Log in / Sign up
Phase 3 N=1,316 Randomized Treatment

Surfactant Positive Airway Pressure and Pulse Oximetry Trial

Infant, Newborn, Diseases · Other Preterm Infants · Infant, Small for Gestational Age · Premature Birth · Bronchopulmonary Dysplasia

Enrolled (actual)
1,316
Serious AEs
67.3%
Results posted
Dec 2014
Primary outcome: Primary: Survival Without Bronchopulmonary Dysplasia (BPD) — 346; 320 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Surfactant (Drug); Continuous Positive Airway Pressure (CPAP) (Device); Supplemental oxygen with target saturation of 85 to 89% (Drug); Supplemental oxygen with target saturation of 91 to 95% (Drug)
Age
Pediatric · 0+ yrs
Sex
All
Sponsor
NICHD Neonatal Research Network
Primary completion
Feb 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Survival Without Bronchopulmonary Dysplasia (BPD)
346; 320
PRIMARY
Survival Without Severe Retinopathy of Prematurity (ROP) (Threshold Disease or the Need for Surgery)
434; 418
SECONDARY
Death or Neurodevelopmental Impairment
173; 183; 185; 171
SECONDARY
Duration of Mechanical Ventilation
11; 13; 7; 11.5
SECONDARY
Survival Without Ventilation
161; 157; 190; 172
SECONDARY
Received Surfactant Treatment
159; 176; 42; 51
SECONDARY
Number of Participants With Air Leaks
26; 22; 25; 20
SECONDARY
Physiological Bronchopulmonary Dysplasia
102; 117; 103; 120
SECONDARY
Death
73; 67; 67; 51
SECONDARY
Severe Intraventricular Hemorrhage (IVH)
34; 38; 49; 43
SECONDARY
Periventricular Leukomalacia (PVL)
10; 16; 14; 14
SECONDARY
Threshold Retinopathy of Prematurity (ROP) Requiring Surgery
19; 44; 17; 47
SECONDARY
Endotracheal Intubation
294; 315; 110; 117
SECONDARY
Duration of Oxygen Supplementation
46; 60; 43; 59
SECONDARY
Pulse Oximetry Values > 90%
62; 76; 63; 77
SECONDARY
Blindness in at Least One Eye
4; 3; 1; 5
SECONDARY
Received Postnatal Steroids
42; 41; 19; 28
SECONDARY
Necrotizing Enterocolitis (NEC)
36; 27; 40; 43
SECONDARY
Cerebral Palsy
17; 17; 26; 24

Summary

This study compared the use of continuous positive airway pressure initiated at birth with the early administration of surfactant administered through a tube in the windpipe within 1 hour of birth for premature infants born at 24 to 27 weeks gestation. In addition, these infants within 2 hours of birth, had a special pulse oximeter placed to continuously monitor their oxygen saturation in two different target ranges (85-89% or 91-95%). This study helped determine whether or not these two management strategies affect chronic lung disease and survival of premature infants.

Eligibility Criteria

Inclusion Criteria

  • Infants with a minimal gestational age of 24 weeks 0 days to 27 completed weeks (up to 27 6/7ths) by best obstetrical estimate
  • Infants who will receive full resuscitation as necessary, i.e., no parental request or physician decision to forego resuscitation
  • Infants whose parents/legal guardians have provided consent for enrollment, or
  • Infants without known major congenital malformations

Exclusion Criteria

  • Any infant transported to the center after delivery
  • Infants whose parents/legal guardians refuse consent
  • Infants born during a time when the research apparatus/study personnel are not available
  • Infants 28 weeks 0 days, completed weeks of gestation
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00233324). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search